These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 20739505)

  • 21. HPV16 mutant E6/E7 construct is protective in mouse model.
    Goodarzi MM; Mosayebi G; Ganji A; Raoufi E; Sadelaji S; Babaei S; Abtahi H
    BMC Biotechnol; 2024 Sep; 24(1):71. PubMed ID: 39350162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens.
    Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
    Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
    J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prime-boost therapeutic vaccination in mice with DNA/DNA or DNA/Fowlpox virus recombinants expressing the Human Papilloma Virus type 16 E6 and E7 mutated proteins fused to the coat protein of Potato virus X.
    Illiano E; Bissa M; Paolini F; Zanotto C; De Giuli Morghen C; Franconi R; Radaelli A; Venuti A
    Virus Res; 2016 Oct; 225():82-90. PubMed ID: 27664839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
    Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
    Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen.
    Yan J; Reichenbach DK; Corbitt N; Hokey DA; Ramanathan MP; McKinney KA; Weiner DB; Sewell D
    Vaccine; 2009 Jan; 27(3):431-40. PubMed ID: 19022315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.
    Sin JI
    Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
    Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
    Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers.
    Lescaille G; Pitoiset F; Macedo R; Baillou C; Huret C; Klatzmann D; Tartour E; Lemoine FM; Bellier B
    Hum Gene Ther; 2013 May; 24(5):533-44. PubMed ID: 23521528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.
    Kim D; Monie A; He L; Tsai YC; Hung CF; Wu TC
    Gene Ther; 2008 May; 15(9):677-87. PubMed ID: 18273057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
    Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
    Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.
    Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D
    J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.
    Wu A; Zeng Q; Kang TH; Peng S; Roosinovich E; Pai SI; Hung CF
    Gene Ther; 2011 Mar; 18(3):304-12. PubMed ID: 20981112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
    Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
    Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
    Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
    Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
    Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
    J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.